Eptifibatide Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IA/0017 
A.7 - Administrative change - Deletion of 
21/04/2023 
manufacturing sites 
Annex II and 
PL 
IA/0014 
B.II.e.2.a - Change in the specification parameters 
03/10/2022 
n/a 
and/or limits of the immediate packaging of the 
finished product - Tightening of specification limits 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
IB/0013 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
12/04/2022 
16/12/2022 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IA/0012 
A.7 - Administrative change - Deletion of 
21/12/2021 
16/12/2022 
Annex II and 
manufacturing sites 
PL 
IA/0011 
B.III.2.b - Change to comply with Ph. Eur. or with a 
19/04/2021 
n/a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
R/0010 
Renewal of the marketing authorisation. 
23/07/2020 
30/09/2020 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
PL 
Eptifibatide Accord in the approved indication remains 
favourable and recommended an unlimited validity for the 
Marketing Authorisation. 
IB/0009 
B.II.e.4.c - Change in shape or dimensions of the 
06/11/2019 
n/a 
container or closure (immediate packaging) - Sterile 
medicinal products 
N/0006 
Minor change in labelling or package leaflet not 
29/04/2019 
21/02/2020 
Labelling 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0008 
B.II.b.2.c.1 - Change to importer, batch release 
05/03/2019 
21/02/2020 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0007/G 
This was an application for a group of variations. 
22/02/2019 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
T/0005 
Transfer of Marketing Authorisation 
18/01/2019 
06/02/2019 
SmPC, 
Labelling and 
PL 
II/0004 
B.II.b.4.d - Change in the batch size (including batch 
12/07/2018 
n/a 
size ranges) of the finished product - The change 
relates to all other pharmaceutical forms 
manufactured by complex manufacturing processes 
II/0003 
B.II.b.4.d - Change in the batch size (including batch 
25/05/2018 
n/a 
size ranges) of the finished product - The change 
relates to all other pharmaceutical forms 
manufactured by complex manufacturing processes 
IA/0002 
A.4 - Administrative change - Change in the name 
24/03/2017 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0001/G 
This was an application for a group of variations. 
03/06/2016 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
